Video
Dr. Nickel discusses the safety of novel recurrent UTI vaccine
Author(s):
“It is a vaccine that is self-administered by the patient sublingual over 3 months, and that is why it appears to be so safe,” says J. Curtis Nickel, MD.
Video Player is loading.
In this video, J. Curtis Nickel, MD, discusses the safety of the MV140 vaccine, used to treat patients with recurrent urinary tract infections. Nickel is a professor of the department of urology at Queen’s University and urologist at Kingston and Hotel Dieu General Hospitals, Kingston, Ontario, Canada.
Related Videos
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Endourologist discusses shared decision-making and laser lithotripsy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Related Content
